SIRPA and neoplasm: Potential strategies that may distinguish the in vivo 18F-FDG PET/CT imaging metabolic changes caused by TAMs from those caused by the tumor cells themselves include administration of treatment modalities that polarize TAMs towards an anti-tumorigenic phenotype, e.g., blocking the CD47-SIRPα axis, or that induce depletion of TAMs in the tumor microenvironment, e.g., biphosphonates and trabectedin [44].